Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials

Journal of Clinical Psychiatry

Volumn 72, Issue 12, 2011, Pages 1660-1668

  Tedeschini, Enrico ^a,b   Levkovitz, Yeciel ^b,c,d   Iovieno, Nadia ^b   Ameral, Victoria E ^b   Nelson, J Craig ^e   Papakostas, George I ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SHALVATA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; PROTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGE DISTRIBUTION; ARTICLE; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; ELDERLY CARE; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84555194678     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10r06531     Document Type: Article

References (51)

1. Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review. BMC Psychiatry. 2009;9(1):31. doi:10.186/1471-24X-9-31 PubMed
2. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127. doi:10.159/069738 PubMed (Pubitemid 36469860)
3. Saunders PA, Copeland JR, Dewey ME, et al. The prevalence of dementia, depression and neurosis in later life: the Liverpool MRC-ALPHA Study. Int J Epidemiol. 1993;22(5):838-847. doi:10.1093/ije/2.5.838 PubMed (Pubitemid 23331094)
4. Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003;58(3):249-265. PubMed (Pubitemid 36307597)
5. Lyness JM, Yu Q, Tang W, et al. Risks for depression onset in primary care elderly patients: potential targets for preventive interventions. Am J Psychiatry. 2009;166(12):1375-1383. doi:10.176/api.ajp.209.08101489 PubMed
6. van Marwijk HW, Ader H, de Haan M, et al. Primary care management of major depression in patients aged ≥55 years: outcome of a randomised clinical trial. Br J Gen Pract. 2008;58(555):680-687. doi:10.39/bjgp08X342165 PubMed
7. Gallo JJ, Bogner HR, Morales KH, et al. Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary-care patients. Am J Geriatr Psychiatry. 2005;13(9):748-755. PubMed
8. Wilson KC, Copeland JR, Taylor S, et al. Natural history of pharmacotherapy of older depressed community residents: the MRC-ALPHA Study. Br J Psychiatry. 1999;175(5):439-443. doi:10.192/bjp.175.5.439 PubMed
9. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? a STAR*D report. Am J Psychiatry. 2009;166(5):599-607. doi:10.176/api.ajp. 208.08071027 PubMed
10. Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007;27(3):295-301. doi:10.1097/JCP.0b013e318058263f PubMed (Pubitemid 46763313)
11. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis. 2004;192(2): 87-94. doi:10.1097/01.nmd.010279.23893.82 PubMed (Pubitemid 38248899)
12. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473. doi:10.176/api.ajp.159.3.469 PubMed (Pubitemid 34184745)
13. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159(2):191-200. doi:10.176/api.ajp.159.2.191 PubMed (Pubitemid 34126894)
14. Partonen T, Sihvo S, Lönnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57(12):572-575. doi:10.408/JCP.v57n1203 PubMed (Pubitemid 27056898)
15. Sullivan PF, Joyce PR. Effects of exclusion criteria in depression treatment studies. J Affect Disord. 1994;32(1):21-26. doi:10.1016/0165-0327(94) 9057-4 PubMed (Pubitemid 24277403)
16. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558-567. doi:10.1097/01.JGP.03083.64832.ed PubMed
17. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009; 19(1):34-40. doi:10.1016/j.euroneuro.208.08.09 PubMed
18. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;(1):CD003491. PubMed
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
22. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782. PubMed (Pubitemid 9064061)
23. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57-63. PubMed
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
26. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
27. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847. doi:10.101/jama.287.14.1840 PubMed (Pubitemid 34303629)
28. Tedeschini E, Fava M, Goodness TM, et al. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. Eur Neuropsychopharmacol. 2010;20(8):562-567. doi:10.1016/j.euroneuro.2010.02.04 PubMed
29. Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41(6):216-220. PubMed (Pubitemid 10120863)
30. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12):1155-1166. doi:10.1016/06-323(86)902-2 PubMed (Pubitemid 16047896)
31. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol. 1995;10(suppl 2):S125-S133. doi:10.102/hup.47010807
32. Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord. 1995;33(1):1-9. doi:10.1016/0165-0327(94)047-D PubMed
33. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. The Fluoxetine Collaborative Study Group. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr. 1995;7(1):89-104. doi:10.1017/S1041610295018 PubMed
34. Schweizer E, Rickels K, Hassman H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry. 1998; 59(4):175-183. doi:10.408/JCP.v59n0406 PubMed (Pubitemid 28208332)
35. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64(9):1065-1074. doi:10.408/JCP.v64n0912 PubMed (Pubitemid 37158252)
36. Schneider LS, Nelson JC, Clary CM, et al. Sertraline Elderly Depression Study Group. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160(7):1277-1285. (Pubitemid 41070944)
37. Roose SP, Sackeim HA, Krishnan KR, et al. Old-Old Depression Study Group. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry. 2004;161(11):2050-2059. (Pubitemid 39441406)
38. Kasper S, de Swart H, Friis-Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry. 2005;13(10):884-891. (Pubitemid 46638677)
39. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14(4):361-370.
40. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164(6):900-909. (Pubitemid 46972905)
41. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14-20.
42. Rapaport MH, Lydiard RB, Pitts CD, et al. Low doses of controlledrelease paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry. 2009;70(1):46-57.
43. Hewett K, Chrzanowski W, Jokinen R, et al. Double-blind, placebocontrolled evaluation of extended-release bupropion in elderly patients with major depressive disorder [published online ahead of print January 22, 2009]. J Psychopharmacol. 2010;24(4):521-529.
44. Alexopoulos GS, Kiosses DN, Murphy C, et al. Executive dysfunction, heart disease burden, and remission of geriatric depression. Neuropsychopharmacology. 2004;29(12):2278-2284. (Pubitemid 39578921)
45. Alexopoulos GS, Kiosses DN, Heo M, et al. Executive dysfunction andthe course of geriatric depression. Biol Psychiatry. 2005;58(3):204-210. (Pubitemid 41112268)
46. Sneed JR, Keilp JG, Brickman AM, et al. The specificity of neuropsychological impairment in predicting antidepressant nonresponse in the very old depressed. Int J Geriatr Psychiatry. 2008;23(3):319-323. (Pubitemid 351418899)
47. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry. 2008;165(2):238-244. (Pubitemid 351704524)
48. Iosifescu DV, Renshaw PF, Lyoo IK, et al. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006;188(2):180-185. (Pubitemid 43171076)
49. Papakostas GI, Iosifescu DV, Renshaw PF, et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (pt 2). Psychiatry Res. 2005;140(3):301-307. (Pubitemid 41660974)
50. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160(12):2122-2127. (Pubitemid 39619604)
51. Pettit JW, Lewinsohn PM, Roberts RE, et al. The long-term course of depression: development of an empirical index and identification of early adult outcomes. Psychol Med. 2009;39(3):403-412.